Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Improving ECG data collection and analysis using high-tech equipment

Our core lab is situated at our clinical unit at London Bridge, offering a focused work environment for TQT trials with no additional costs, thereby delivering value for money to pharmaceutical sponsors.

We use FDA compliant MAC 2000 resting ECGs and Digital12-Lead Holter devices for collection, transmission and processing of digital ECG and Holter recordings for TQT studies. Each bedside has a GE MAC 2000, 12-lead ECG machine connected to the MUSE® Server allowing for storage of thousands of digital ECG’s. These digitised ECG's are available to our cardiological sciences team as required for subsequent digitised reading, analysis and reporting. The system is FDA 21 CFR Part 11 compliant with secure authorized user access and password protection to allow access to users for their required access levels only. A detailed audit trail is available and includes the username, date and time of access of any individual using the system and what addition or change they made to the database.

The digital 12-Lead ECG machines used for our studies are configured to ensure every ECG data file contains the exact and correct information in FDA compliant format (HL7) as per ICH E14. The configuration of each machine used in our TQT studies undergoes a vigorous validation process, including acquisition and transfer of test ECGs from the machine’s simulator. The standard configuration and validation process is fully documented and available to clients upon request.

Producing data you can trust, using the latest equipment.

Get in touch today

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event